Published in Nat Med on July 01, 1996
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Principles and applications of methods for DNA-based typing of microbial organisms. J Clin Microbiol (1999) 5.88
Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A (1999) 5.63
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother (2000) 3.54
Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol (1999) 3.32
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol (1998) 2.92
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
Typing and subtyping influenza virus using DNA microarrays and multiplex reverse transcriptase PCR. J Clin Microbiol (2001) 2.69
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol (1999) 2.65
Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (1999) 2.63
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol (1999) 2.51
Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis. Clin Microbiol Rev (1998) 2.48
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Res (2006) 2.11
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08
Mutational analysis using oligonucleotide microarrays. J Med Genet (1999) 2.05
Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One (2009) 1.91
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS (2008) 1.91
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One (2010) 1.83
Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol (2001) 1.79
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol (2001) 1.75
Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol (1998) 1.75
Basic concepts of microarrays and potential applications in clinical microbiology. Clin Microbiol Rev (2009) 1.70
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol (2000) 1.70
Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol (2002) 1.66
Molecular aspects of severe malaria. Clin Microbiol Rev (2000) 1.64
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother (2004) 1.54
A miniature integrated device for automated multistep genetic assays. Nucleic Acids Res (2000) 1.51
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol (1999) 1.50
Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc Natl Acad Sci U S A (1996) 1.48
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 1.45
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
Population dynamics of HIV-1 inferred from gene sequences. Genetics (1999) 1.43
Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol (2000) 1.38
Portable system for microbial sample preparation and oligonucleotide microarray analysis. Appl Environ Microbiol (2001) 1.36
Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev (2007) 1.31
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol (2005) 1.29
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol (1999) 1.27
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother (2002) 1.27
Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol (2001) 1.22
Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucleic Acids Res (2005) 1.20
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol (2004) 1.15
Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol (1999) 1.13
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol (1999) 1.12
Use of resequencing oligonucleotide microarrays for identification of Streptococcus pyogenes and associated antibiotic resistance determinants. J Clin Microbiol (2005) 1.11
DNA probe array for the simultaneous identification of herpesviruses, enteroviruses, and flaviviruses. J Clin Microbiol (2005) 1.08
Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. Biol Direct (2006) 1.06
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol (2006) 1.06
DNA microarrays in medical practice. BMJ (2001) 1.05
Science, medicine, and the future. Near patient microbiological tests. BMJ (1999) 1.04
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (2000) 1.02
Genetic screening with the DNA chip: a new Pandora's box? J Med Ethics (1999) 1.02
Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants. BMC Mol Biol (2008) 1.01
A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother (1997) 1.01
Parallel assessment of CpG methylation by two-color hybridization with oligonucleotide arrays. Anal Biochem (2002) 1.01
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol (2005) 0.97
Application of broad-spectrum, sequence-based pathogen identification in an urban population. PLoS One (2007) 0.97
Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob Agents Chemother (1999) 0.97
Arrays of arrays for high-throughput gene expression profiling. Genome Res (2001) 0.95
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Microarrays for genotyping human group a rotavirus by multiplex capture and type-specific primer extension. J Clin Microbiol (2003) 0.93
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology (2012) 0.91
Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother (2001) 0.90
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob Agents Chemother (1998) 0.87
Molecular Techniques in the Diagnosis of Central Nervous System Infections. Curr Infect Dis Rep (2002) 0.87
Antiretroviral Drug Resistance in HIV-1. Curr Infect Dis Rep (1999) 0.87
Polymorphism in the mitochondrial cytochrome B gene in Koreans. An additional marker for individual identification. Int J Legal Med (2002) 0.85
Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers. AIDS Res Hum Retroviruses (2012) 0.84
An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir. Antimicrob Agents Chemother (1998) 0.84
Focused microarray analysis of peripheral mononuclear blood cells from Churg-Strauss syndrome patients. DNA Res (2008) 0.83
Functional genomics as a tool in virus research. Indian J Microbiol (2008) 0.82
Application of molecular diagnostic techniques for viral testing. Open Virol J (2012) 0.81
Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment. BMC Genomics (2006) 0.81
Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci (1999) 0.80
Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays. J Clin Microbiol (2004) 0.79
Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med (2013) 0.79
Molecular bacteriology: a diagnostic tool for the millennium. J Clin Pathol (2000) 0.79
Molecular genetics of Psoriasis (Principles, technology, gene location, genetic polymorphism and gene expression). Int J Health Sci (Qassim) (2010) 0.79
Simple PCR-based DNA microarray system to identify human pathogenic fungi in skin. J Clin Microbiol (2010) 0.79
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen. Antimicrob Agents Chemother (2003) 0.78
Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One (2014) 0.77
Microbial genome sequencing-beyond the double helix. BMJ (1998) 0.76
An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS One (2016) 0.75
HIV drug resistance: genotypic assays and their possible applications. Sex Transm Infect (1998) 0.75
Advanced computational techniques for re-sequencing DNA with polymerase signaling assay arrays. Nucleic Acids Res (2003) 0.75
Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr (2010) 0.75
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
High density synthetic oligonucleotide arrays. Nat Genet (1999) 29.99
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science (1998) 18.23
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet (1999) 17.09
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Computer programs for the assembly of DNA sequences. Nucleic Acids Res (1979) 13.36
Using oligonucleotide probe arrays to access genetic diversity. Biotechniques (1995) 12.18
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Steps toward computer analysis of nucleotide sequences. Science (1980) 8.73
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Elution of DNA from agarose gels after electrophoresis. Methods Enzymol (1979) 8.36
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics (2002) 5.88
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci U S A (1990) 5.85
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat Genet (1996) 5.77
Nucleotide sequences from the adenovirus-2 genome. J Biol Chem (1982) 5.76
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Early discharge after hernia repair. Lancet (1968) 5.29
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med (1992) 4.71
Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat Genet (2000) 4.66
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia (2000) 4.42
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med (1997) 4.27
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr (2000) 4.03
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med (2001) 3.75
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med (1989) 3.63
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. Proc Natl Acad Sci U S A (1989) 3.56
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
Chaotic Dirac billiard in graphene quantum dots. Science (2008) 3.53
Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A (2000) 3.47
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Comparing genomes within the species Mycobacterium tuberculosis. Genome Res (2001) 3.40
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol (1995) 3.18
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia (2009) 2.94
The isolation and characterization of the Escherichia coli DNA adenine methylase (dam) gene. Nucleic Acids Res (1983) 2.94
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Language discrimination by human newborns and by cotton-top tamarin monkeys. Science (2000) 2.89
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol (1985) (1992) 2.85
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood (1992) 2.77
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest (1997) 2.69
Sources of absorption and scattering contrast for near-infrared optical mammography. Acad Radiol (2001) 2.66
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol (1999) 2.65
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Discrepant legacies: premature mortality in two industrial towns. Soc Sci Med (1991) 2.62
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62